Aida Pharmaceuticals Inc. (AIDA)

Overview

Aida Pharmaceuticals, Inc., established in 1999 and operating from Hangzhou, China, comprises several subsidiaries dedicated to the pharmaceutical and genetic product industry within mainland China. The company focuses on the research, development, formulation, clinical testing, registration, manufacturing, sales, and marketing of an extensive range of pharmaceutical products. Aida Pharmaceuticals has carved out a niche in providing innovative solutions in the healthcare sector with a product line that includes antibiotics, cardiovascular medications, and anti-cancer drugs, catering to the diverse medical needs of the population.

Products and Services

• Etimicin Sulfate - This product is presented as an injectable powder form, primarily focused on treating various bacterial infections. Etimicin Sulfate is recognized for its enhanced potency and reduced nephrotoxicity compared to other aminoglycoside antibiotics, making it a preferred choice in clinical settings for combating serious infections.
• rh-Apo2L - As a part of Aida Pharmaceuticals' foray into biopharmaceuticals, rh-Apo2L represents a cutting-edge therapy for the treatment of cancers. This recombinant humanized protein targets and induces apoptosis in cancer cells, offering hope as a novel cancer therapy with the potential to change the landscape of cancer treatment.
• Antibiotics - Apart from Etimicin Sulfate, Aida Pharmaceuticals provides a broad spectrum of antibiotic drugs designed to treat various infections. These antibiotics come in different forms, including powder for injection and tablets, ensuring flexibility in administration and therapy customization based on patient needs.
• Cardiovascular Drugs - The company's cardiovascular product line addresses a range of heart and blood vessel conditions, offering both preventive and treatment options in the form of capsules, tablets, and injections. These medications are crucial for managing conditions such as hypertension, heart failure, and arrhythmias, contributing significantly to patient care in cardiovascular disease.
• Anti-Cancer Drugs - In addition to rh-Apo2L, Aida Pharmaceuticals has developed other anti-cancer medications in various forms, including liquid for intravenous injection and tablets. These drugs are developed to meet the growing need for effective cancer treatments and are part of the company's comprehensive approach to cancer therapy, targeting different types of cancer with the aim of improving patient outcomes and quality of life.